Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review
TLDR
To reduce the disease burden of HBV infection among HIV-infected patients, adoption of safe sex practices, avoidance of sharing needles and diluent, HBV vaccination and use of cART containing tenofovir disoproxil fumarate plus emtricitabine or lamivudine are the most effective approaches.Abstract:
Hepatitis B virus (HBV) infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. Due to the shared modes of transmission, coinfection with HBV and human immunodeficiency virus (HIV) is not uncommon. It is estimated that 10% of HIV-infected patients worldwide are coinfected with HBV. In areas where an HBV vaccination program is implemented, the HBV seroprevalence has declined significantly. In HIV/HBV-coinfected patients, HBV coinfection accelerates immunologic and clinical progression of HIV infection and increases the risk of hepatotoxicity when combination antiretroviral therapy (cART) is initiated, while HIV infection increases the risk of hepatitis events, cirrhosis, and end-stage liver disease related to chronic HBV infection. With the advances in antiviral therapy, concurrent, successful long-term suppression of HIV and HBV replication can be achieved in the cART era. To reduce the disease burden of HBV infection among HIV-infected patients, adoption of safe sex practices, avoidance of sharing needles and diluent, HBV vaccination and use of cART containing tenofovir disoproxil fumarate plus emtricitabine or lamivudine are the most effective approaches. However, due to HIV-related immunosuppression, using increased doses of HBV vaccine and novel approaches to HBV vaccination are needed to improve the immunogenicity of HBV vaccine among HIV-infected patients.read more
Citations
More filters
Journal Article
Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. Commentary
Karine Lacombe,Véronique Massari,Pierre-Marie Girard,Lawrence Serfaty,Joël Gozlan,Gilles Pialoux,Patrick Mialhes,Jean-Michel Molina,Caroline Lascoux-Combe,Dominique Wendum,Fabrice Carrat,Fabien Zoulim,Vincent Soriano,Julie Sheldon,Belén Ramos,Marina Núñez +15 more
TL;DR: In this article, a cross-sectional analysis examined common characteristics of hepatitis B virus infection in an ongoing cohort study of 308 patients with both HIV-1-positive Western blot and plasma HBV surface antigen (HBsAg) seropositivity.
Journal ArticleDOI
Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies
Keri N. Althoff,Kelly A. Gebo,Richard D. Moore,Cynthia M. Boyd,Amy C. Justice,Amy C. Justice,Cherise Wong,Gregory M. Lucas,Marina B. Klein,Mari M. Kitahata,Heidi M. Crane,Michael J. Silverberg,M. John Gill,William C. Mathews,Robert Dubrow,Michael A. Horberg,Charles S. Rabkin,Daniel B. Klein,Vincent Lo Re,Timothy R. Sterling,Fidel A Desir,Kenneth A. Lichtenstein,James H. Willig,Anita Rachlis,Gregory D. Kirk,Kathryn Anastos,Frank J. Palella,Jennifer E. Thorne,Joseph J. Eron,Lisa P. Jacobson,Sonia Napravnik,Chad J. Achenbach,Angel M. Mayor,Pragna Patel,Kate Buchacz,Yuezhou Jing,Stephen J. Gange +36 more
TL;DR: The substantial proportion of non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-Stage renal disease outcomes that could be prevented with interventions on traditional risk factors elevates the importance of screening for these risk factors.
Journal ArticleDOI
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America from the Early to Modern Antiretroviral Therapy Eras
Marina B. Klein,Keri N. Althoff,Yuezhou Jing,Bryan Lau,Mari M. Kitahata,Vincent Lo Re,Gregory D. Kirk,Mark Hull,H. Nina Kim,Giada Sebastiani,Erica E. M. Moodie,Michael J. Silverberg,Timothy R. Sterling,Jennifer E. Thorne,Angela Cescon,Sonia Napravnik,J. J. Eron,M. John Gill,Amy C. Justice,Marion G. Peters,James J. Goedert,Angel M. Mayor,Chloe L. Thio,Edward R. Cachay,Richard D. Moore +24 more
TL;DR: Despite increasing use of antiretrovirals, no clear reduction in ESLD risk was observed over 15 years and treatment with direct-acting antivirals for HCV and wider use of tenofovir-based regimens for HBV should be prioritized for coinfected patients.
Journal ArticleDOI
Hepatitis B and A vaccination in HIV-infected adults: A review
TL;DR: The duration of the response to both HBV and HAV vaccines is associated with suppression of the viral load at vaccination and, in the case of HBV vaccination, with a higher level of antibodies after vaccination.
Journal ArticleDOI
Aging with HIV in the ART era
TL;DR: This review hopes to describe the current comorbidities occurring among PLWH and bring increased awareness for conditions that may otherwise not be considered given the younger age at time of presentation.
References
More filters
Journal ArticleDOI
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
Anthony S. Fauci,John G. Bartlett,Eric P. Goosby,M. D. Smith,H. J. Kaiser,S. W. Chang,James M. Anderson,R. Armstead,A. C. Baker,David A Barr,Samuel A. Bozzette,S. Cox,M. Delaney,Fred M. Gordin,W. Greaves,M. Harrington,J. J. Henning,Martin S. Hirsch,J. Jacobs,Richard Marlink,C. Maxwell,J. W. Mellors,D. B. Nash,S. Perryman,Robert T. Schooley,R. Sherer,Stephen A. Spector,G. Torres,Paul A. Volberding,B. A. Brady,E. M. Daniels,D. Feigal,Mark B. Feinberg,H. D. Gayle,T. R. Graydon,Jonathan E. Kaplan,Abe M. Macher,R. F. Martin,Henry Masur,Lynne M. Mofenson,J. Murray,J. O'Neill,L. C. Perez,R. Riseberg,S. Shekar,Sharilyn K. Stanley,J. Whitescarver +46 more
TL;DR: These Guidelines were developed by the Panel* on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation.
Journal ArticleDOI
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
Chien-Jen Chen,Hwai I. Yang,Jun Su,C.-L. Jen,San Lin You,Sheng-Nan Lu,Guan-Tarn Huang,Uchenna H. Iloeje +7 more
TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.
Journal ArticleDOI
Hepatitis B virus infection.
TL;DR: This review addresses many aspects of HBV infection, including the role of the immune system in determining the outcome of clinical infection, recent developments in molecular studies of the virus, and new treatments capable of eradicating chronic infection.
Journal ArticleDOI
Chronic hepatitis B: Update 2009
Anna S.F. Lok,Brian J. McMahon +1 more
TL;DR: The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines for Management of Chronic Hepatitis B is now posted online at www.aasld.org, and the recommendation for first-line oral antiviral medications has been changed to tenofovir or entecavir, and adefovir has been moved to second-line Oral antiviral medication.
Journal ArticleDOI
Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.
Mei-Hwei Chang,Chien-Jen Chen,Mei-Shu Lai,Hsu-Mei Hsu,Tzee-Chung Wu,Man-Shan Kong,Der-Cherng Liang,Wen-Yi Shau,Ding-Shinn Chen +8 more
TL;DR: The incidence of hepatocellular carcinoma in children in Taiwan from 1981 to 1994 has declined since the institution of Taiwan's program of universal hepatitis B vaccination, and the corresponding rates of mortality have decreased.